Attack of the Clones: CHIP in the Clinic
In this No Data Zone piece, Drs. Rafael Bejar and Mikkael Sekeres discuss CHIP in aging patients, with next steps for real-world treatment strategies.
A New Standard of Care for Children and Young Adults With T-cell Acute Lymphoblastic Leukemia
Dr. Teachey reviews a study that shows outstanding outcomes for children and young adults with T-cell acute lymphoblastic leukemia that have raised the bar and established
At 7:00 p.m. on Saturday, January 19, some sections of the ASH website will be taken down for scheduled service upgrades. During this time, visitors will not be able to register for ASH events or view content that requires login with an ASH Account. ASH Customer Service will also not be available on Monday, January 21st. Full service will be restored on Tuesday, January 22.
Drs. Taylor and Abdel-Wahab look back at studies from 2018 that show great progress in therapies for myelodysplastic syndromes.
Dr. DeBaun sheds light on advancements in the field of sickle cell disease, including drug approvals and ongoing trials.
Dr. Michaelis and Prof. Roberts discuss advancements relating to clonal hematopoiesis of indeterminate potential, or CHIP, from 2018.
January/February 2019Volume 16, Issue 1
View all Features articles
View all Diffusion articles
In his inaugural President's Column, Dr. Roy Silverstein reflects on the Society's accomplishments and sets priorities for the coming year.
View all president's column articles
View all Ask the Hematologist articles
View all Clinical Trials Corner articles
View all Mini Review articles
ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.
ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.
In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.
In 2018, ASH commented on numerous rules and regulations proposed by the Centers for Medicare and Medicaid Services (CMS), which impact physician payment. ASH is actively involved in various advisory committees and also continues to engage with lawmakers on Capitol Hill.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology